問卷

TPIDB > Search Result

Search Result

篩選

List

93Cases

2025-04-01 - 2027-12-31

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential administration of THIO and Cemiplimab (LIBTAYO®) versus single-agent chemotherapy of the trial administrator's choice in advanced/metastatic non-small cell lung cancer (NSCLC).
  • Condition/Disease

    OS (defined as the time elapsed from random assignment to death for any reason)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2020-12-01 - 2027-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2007-11-14 - 2009-12-29

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2019-03-18 - 2024-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2025-06-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-01-01 - 2028-01-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

2024-05-01 - 2030-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-11-01 - 2028-03-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2022-08-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2024-06-01 - 2027-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites